Have a personal or library account? Click to login
Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk Cover

Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk

Acta Pharmaceutica
Volume 72 (2022): Issue 2 (June 2022)
By: ANA VAVLUKIS,  MARIJA VAVLUKIS,  ALEKSANDAR DIMOVSKI,  GORDANA PETRUSHEVSKA,  ALEKSANDAR EFTIMOV,  SASHKA DOMAZETOVSKA and  KRISTINA MLADENOVSKA  
Open Access
|Dec 2021
DOI: https://doi.org/10.2478/acph-2022-0018 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English
Page range: 303 - 315
Accepted on: Jun 21, 2021
|
Published on: Dec 30, 2021
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
rosuvastatin,
vascular endothelial growth factor,
epidermal growth factor,
cardiovascular risk
Related subjects:
Pharmacy,
Pharmacy, other

© 2021 ANA VAVLUKIS, MARIJA VAVLUKIS, ALEKSANDAR DIMOVSKI, GORDANA PETRUSHEVSKA, ALEKSANDAR EFTIMOV, SASHKA DOMAZETOVSKA, KRISTINA MLADENOVSKA, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 72 (2022): Issue 2 (June 2022)Next article